# CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy

> **NCT02013817** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 43 (actual)

## Conditions studied

- Lymphocytic Leukemia, Chronic

## Interventions

- **DRUG:** rituximab [MabThera/Rituxan]
- **DRUG:** fludarabine
- **DRUG:** cyclophosphamide

## Key facts

- **NCT ID:** NCT02013817
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10-11
- **Primary completion:** 2012-09-24
- **Final completion:** 2012-09-24
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2017-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02013817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02013817, "CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT02013817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*